Antiprotozoal agents: How have they changed over a decade?

Vitória de Souza Fernandes, Rafael da Rosa, Lara A. Zimmermann, Kamilla R. Rogério, Arthur E. Kümmerle, Lilian S. C. Bernardes (Lead / Corresponding author), Cedric S. Graebin (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)

Abstract

Neglected tropical diseases are a diverse group of communicable diseases that are endemic in low- or low-to-middle-income countries located in tropical and subtropical zones. The number and availability of drugs for treating these diseases are low, the administration route is inconvenient in some cases, and most of them have safety, efficacy, or adverse/toxic reaction issues. The need for developing new drugs to deal with these issues is clear, but one of the most drastic consequences of this negligence is the lack of interest in the research and development of new therapeutic options among major pharmaceutical companies. Positive changes have been achieved over the last few years, although the overall situation remains alarming. After more than one decade since the original work reviewing antiprotozoal agents came to light, now it is time to question ourselves: How has the scenario for the treatment of protozoal diseases such as malaria, leishmaniasis, human African trypanosomiasis, and American trypanosomiasis changed? This review covers the last decade in terms of the drugs currently available for the treatment of these diseases as well as the clinical candidates being currently investigated.

Original languageEnglish
Article number2100338
JournalArchiv der Pharmazie
Volume355
Issue number2
DOIs
Publication statusPublished - 1 Feb 2022

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Antiprotozoal agents: How have they changed over a decade?'. Together they form a unique fingerprint.

Cite this